Researchers from CAMO-Net UK have developed a uniquely portable and rapid molecular diagnostic tool with the potential to revolutionise the way infectious diseases are identified around the world. Effective pathogen diagnostics begins with extracting high-quality nucleic acids.
The team, led by Dr Jesus Rodriguez Manzano from the Department of Infectious Disease at Imperial College London, and Co-founder/CSO of ProtonDx Ltd, an Imperial spin-out, have developed SmartLid, an innovative power-free system designed for rapid, high-quality extraction of nucleic acids, such as DNA or RNA, which is suitable for point-of-care (POC) use.
The global need for bringing portable and accurate diagnostic systems directly to the POC has never been greater, with recent challenging outbreaks such as Dengue Fever, Malaria, MPOX, Influenza, and SARS-CoV-2 catching the world off-guard and unprepared. Seasonal respiratory infections, in particular, present a major public health challenge due to their high transmissibility and diverse overlapping symptoms. Accurate and rapid diagnosis is essential to manage outbreaks effectively, as delays can exacerbate the spread and impact, leading to potential pandemic situations, such as COVID-19.
Current diagnostic methods, primarily molecular nucleic acid-based tests like real-time PCR, are the gold standard due to their high sensitivity and specificity. However, these methods are often complex, time-consuming, and require sophisticated laboratory infrastructure, making them less accessible in resource-limited settings.
To address these limitations, Dr Jesus Rodriguez Manzano, along with Imperial and ProtonDx colleagues Dr Ivana Pennisi and Dr Matthew Cavuto, developed SmartLid. While the technology was initially intended to accompany ProtonDx’s novel POC molecular diagnostic platform, called Dragonfly, SmartLid was more recently rolled-out as a stand-alone nucleic acid extraction offering aimed at the research sector. The original conception and validation of SmartLid was recently published in the Journal of Analytical Chemistry, co-first authored by Pennisi and Cavuto.
The SmartLid kit includes a proprietary magnetic lid that fits off-the-shelf consumable tubes, ensuring adaptability across different settings. It uses the industry’s fastest magnetic nanoparticles, TurboBeads, to make extracting nucleic acids rapid and easy, with just three simple steps: lysis (breaking open cells and microbes), wash (removing unwanted biomolecules), and elution (collecting and concentrating the DNA/RNA). This setup allows for quick, affordable, and portable sample preparation without needing special equipment or advanced training. The entire process takes less than 5 minutes, compared to the 30-90 minutes required by traditional methods.
By enabling rapid and precise diagnosis of infectious diseases, particularly in resource-limited settings, the SmartLid technology could also support targeted antimicrobial treatment, thereby reducing unnecessary antibiotic use. This approach is pivotal in addressing antimicrobial resistance (AMR), as it promotes more accurate identification of pathogens and facilitates tailored treatment strategies. CAMO-Net’s global efforts to optimise antimicrobial use are complemented by innovations like SmartLid, underscoring the critical role of advanced diagnostics in safeguarding the effectiveness of antimicrobial therapies worldwide.
Dr Jesus Rodriguez-Manzano is a Senior Lecturer in the Department of Infectious Disease at Imperial College London and Deputy Director at the Centre for Antimicrobial Optimisation (CAMO). His research focuses on developing innovative molecular diagnostic tools for infectious diseases and antimicrobial resistance. His work spans the intersection of hardware, software, and molecular science, aiming to improve clinical outcomes and reduce unnecessary antimicrobial use.
Dr Rodriguez Manzano said, “”By enabling rapid and reliable nucleic acid extraction without the need for sophisticated equipment, the SmartLid kit has the potential to transform how infectious diseases are diagnosed, particularly in resource-limited settings. This innovation could significantly expedite the identification of pathogens, helping to curb outbreaks swiftly and effectively, and to optimise antibiotic use in the treatment of appropriate infections.”
The SmartLid kit represents a significant advancement in the rapid, accessible, and affordable extraction and preparation of nucleic acids for diagnostic testing. Its simple, portable, and power-free operation makes it particularly suitable for POC use, providing a viable alternative to traditional laboratory-based methods. The SmartLid kit offers substantial benefits in terms of speed, cost, and practicality, especially in resource-limited settings. As such, it holds promise for improving the management of emerging infectious outbreaks and enhancing global diagnostic capabilities.
You can read more about SmartLid, including the research behind this innovation, in the journal Analytical Chemistry.
